Management Certification

The undersigned, on behalf of Health Advance Inc ("the Company"), certifies that the information provided herein is accurate and complete to the best of the Company's knowledge.

1. The Company is current in its disclosure obligations pursuant to the following reporting standard:

SEC Reporting Obligations

- ○ The Company has a reporting obligation under Section 13 or 15(d) of the Exchange Act
- ○ The Company has a reporting obligation under Regulation A (Tier 2)
- ○ The Company has a reporting obligation under Regulation Crowdfunding (CF)
- ○ Other (please describe) [ ]

Other Reporting Obligations

- ○ The Company is a U.S. bank, bank holding company, or similar financial institution exempt from SEC registration, has a reporting obligation to a U.S. Bank Regulator and follows OTC Markets' Bank Reporting requirements.
- ◉ The Company is exempt from SEC registration and is reporting under the Alternative Reporting Standard

2. Indicate below whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

   Yes: [☐] No: [☒]

3. Indicate below whether the Company is subject to Bankruptcy or reorganization proceedings.

   Yes: [☐] No: [☒]

4. The Company has a Verified Company Profile on OTCMarkets.com.

5. The Company is duly organized and in good standing under the laws of the state or jurisdiction in which the Company is organized or does business.

6. The Company understands and acknowledges its obligations to report company-related actions pursuant to Exchange Act Rule 10b-17 and FINRA Rule 6490.

7. The Company understands and acknowledges its obligations to publicly disclose material information in a timely manner in accordance with applicable U.S. federal securities laws, including but not limited to Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.

8. The Company's transfer agent and its address are listed below. If the Company acts as its own transfer agent, indicate that by listing the Company and its information in the fields provided.[1]

   Transfer Agent: Equity Trust Company, LLC
   Address: 48 Wall Street, Floor 23
   New York, New York
   10005

[1] OTCQX, OTCQB, and OTCID companies are required to retain a transfer agent that participates in the Transfer Agent Verified Shares Program. OTCID companies that act as their own transfer agent may submit data directly to OTC Markets.

9. The Company’s most recent Annual Report was prepared by:

Below is a list all law firm(s) and attorney(s) (including internal counsel) that acted as the Company’s primary legal counsel in preparing its most recent annual report or, if no attorney assisted in preparing the disclosure, the person(s) who prepared the disclosure and their relationship to the Company.

Larry McLachlin

10. The Company’s Officers, Directors and 5% Beneficial Owners are listed below:

The table below provides information regarding all officers and directors of the Company, or any person that performs a similar function, regardless of the number of shares they own. To the best of the Company’s knowledge, it includes all individuals or entities beneficially owning 5% or more of any class of the issuer’s equity securities. To identify holders of 5% or more, companies may obtain a recent copy of their shareholder list that includes Non-Objecting Beneficial Owners or “NOBOs.” SEC Reporting companies may also research their beneficial ownership and insider transaction filings such as on Schedules 13G or 13D or on Forms 3, 4, and 5.

As of (latest practicable date): August 23, 2026

Individual Name (First, Last) **or Entity Name** (Include names of control person(s) if a corporate entity)	**Position/Company Affiliation** (ex: CEO, ≥ 5% beneficial owner)	**City and State** (Include Country if outside U.S.)	**Number of Shares Owned** (List common, preferred, warrants and options separately)	**Class of Shares Owned**	**Percentage of Class of Shares Owned** (undiluted)
Larry McLachlin	President, Director	Collingwood, Ontario, Canada	80,000	Common	.00008%

Any additional material details, including conversion terms of any class of the issuer’s equity securities, are below:

Mr. McLachlin will be provided with Preferred Shares before Dec 31, 2026

11. The Company has Convertible Debt as detailed below:

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

[☐] Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance ($)	Outstanding Balance ($) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism to determine conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion[6]	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
Mar 10/17	10,000	15,337	Mar 03/18	40% Disc	0	64,000,000	GHS Investments Mark Grober	Note 1
Mar 20/19	2,500	62,000	Mar 20/20	TBD	0	0	Fit For A King Gerry Pettle	Note 2
May 25/21	20,697	20,697	May 25/22	$0.025	0	828,000	Sydney Bernstein	Note 3
May 27/21	20,697	20,697	May 27/22	$0.025	0	828,000	Arthur Stemmerman	Note 4
Jun 02/21	20,697	20,697	Jun 02/22	$0.025	0	828,000	Originally Luigi Buttino; Purchased by Gerald Pettle	Note 5
Jul 07/21	20,697	20,697	Jul 07/22	$0.025	0	828,000	Ne'eman Foundation Charm Katz	Note 6
Oct 21/21	72,000	0	Oct 21/22	40% Disc	529,040,547	N/A	JP Carey Limited Partnership Joe Canouse	Note 7
Jan 27/22	57,000	11,467	Jan 27/23	40% Disc	710.916,666	650,000,000	JP Carey Limited Partnership Joe Canouse	
Total Outstanding Balance:		**$171,592**	**TotalShares:**		**1,239,957,213**	**2,859,866,666**		

Any additional material details, including footnotes to the table are below :

[6] The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

Commentary Note 1
The holder has agreed to convert for equity when suitable and possible.

Note 2
Fit For A King, Inc, the owner of record of approximately 30 million common shares, and Fit For A King's beneficial owner, Gerald Pettle, undertook to provide the issuer with working capital in 2019, and thereafter. This was to be for the purpose of attaining OTC Markets current information designation, as well as for the issuer to attain good standing with any other applicable regulatory bodies and suppliers. Compensation to Mr. Pettle is to be eventual repayment in cash with bonus and/or shares, to be determined. Additional possible financial compensation to Mr. Pettle was to be linked to, and/or governed by, the success of business ventures that Mr. Pettle would bring to the issuer in the past, present or future. Such compensation can also either take the form of cash and/or shares. Compensation to Mr. Pettle for earlier assistance will be determined by the issuer's circumstances at the time(s) that compensation to Mr. Pettle is made. Determinations at such time(s) will also take into account compensation required for 3rd parties who are performing supportive interim roles, including retaining OTC Markets good standing, paying other regulatory compliance costs, retiring creditor obligations, and funding or operating business projects. This accommodation of 3rd parties will include compensation to issuer management to market norm standards currently and retroactively, third-party consultants, and any other compensatory arrangements with parties, including staff, who contribute in the interim to attainment of the issuer's goals, or payment by them on behalf of the issuer for costs or processes needed to operate the issuer's business. This debt note is included in the "convertible debt" table not because the debt is immediately convertible but rather that it may become convertible in the future under terms that are not yet known, and are not presently enforceable.

Note 3
At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion.

Note 4
At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion.

Note 5
At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion and that the note may have been purchased by Gerald Pettle.

Note 6
At the time of the filing of this report, management believes that the creditor prefers to receive repayment in cash, rather than conversion.

Note 7
This convertible promissory note has been paid in full.

Signature:

Name of Principal Executive Officer or Principal Financial Officer: Larry McLachlin

Title: President

Date: August 23, 2026

Signature: /s/ Larry McLachlin

(Digital Signatures should appear as "/s/ [OFFICER NAME]")